TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A depressive episode according to DSM-V criteria in the course of a bipolar disorder~* MADRS score \> 17~* Already on a mood stabilizer and/or antidepressant~* Patient with a normal or controlled thyroid function~* Male or female both using effective methods of contraception during treatment if sexually active.~Exclusion Criteria:~* - Contraindication to IL-101 therapy:~* Hypersensitivity to active substance or excipient;~* Active infection requiring antibiotics therapy;~* Organ failure (e.g., liver, kidney, lung and heart);~* Immunosuppressed patient~* Hepatotoxic, nephrotoxic, myelotoxic or cardiotoxic drugs~* Other chronic diseases~* Signs of active infection requiring treatment~* Previous history of organ transplantation~* Leukocytes \< 4000 / mm3, platelets \< 100 000 / mm3, Hemoglobin \< 10.0 g/dL or 6.2 mmol/L, red cell blood \< 3.5 T/L.~* Anti-TPO or anti-TG or anti-TRACKS positive at inclusion.~* Use of anti-inflammatory medication on a regular basis for a chronic inflammatory/autoimmune Disorder (NSAD, immunosuppressant IV-Ig based treatment);~* Ongoing fever \< 38~* uncontrolled diabetes type I or II;~* Existing cancer or history of cancer in the last 5 years (except skin epidermoid cancer or in-situ cervix cancer);~* Existing or planned pregnancy or lactation;~* Person under legal protection (1121-8 of CSP, Public Health Code~* Pregnant and parturient and Breast feeding women (1121-5 of CSP)~* legally detained person (1121-6 of CSP)~* hospitalisation without consent~* under the age of majority (1121-7of CSP)~* Immediate risk for suicidal behaviour (MADRS-item 10 \>2 or columbia \> 2 for suicide idea);~* Known HIV infection or clinically manifest Acquired Immune Deficiency Syndrome (AIDS), Parkinson's or Alzheimer's disease, or any other serious condition likely to interfere with the conduct of the trial;~* Participation to an interventional study concomitantly or within 30 days prior to this study, except in the cohorts studies aiming at the analysis of immuno-inflammatory biomarkers and/or brain imaging studies.~* Patients thought to be unreliable or incapable of complying with the requirements of the protocol;~* Patient is relative of, or staff directly reporting to the investigator;~* Patient is employee of the sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- active treatment (Type: EXPERIMENTAL): IL-2 (ILT-101) Sub-cutaneous~1 million UI/j
- placebo (Type: PLACEBO_COMPARATOR): placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study~* Male or female patients ≥ 50 years of age at screening who are treatment naive~* Active choroidal neovascularization (CNV) secondary to AMD that affects the central subfield, including retinal angiomatous proliferation (RAP) with a CNV component, confirmed by presence of active leakage from CNV seen by fluorescein angiography and sequellae of CNV, e.g. pigment epithelial detachment (PED), subretinal or sub-retinal pigment epithelium (sub-RPE) hemorrhage, blocked fluorescence, macular edema (study eye)~* Presence of intraretinal fluid (IRF) or subretinal fluid (SRF) that affects the central subfield, as seen by Spectral Domain Optical Coherence Tomography (SD-OCT) (study eye)~* Best-corrected visual acuity (BCVA) score between 83 and 38 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at both screening and baseline visit (study eye)~Exclusion Criteria:~* Ocular conditions/disorders at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require planned medical or surgical intervention during the first 12-month study period, structural damage of the fovea, atrophy or fibrosis at the center of the fovea (study eye)~* Any active intraocular or periocular infection or active intraocular inflammation, at screening or baseline (study eye)~* Uncontrolled glaucoma defined as intraocular pressure (IOP) \> 25 mmHg on medication, or according to investigator's judgment, at screening or baseline (study eye)~* Ocular treatments: previous treatment with any anti-vascular endothelial growth factor (VEGF) drugs or investigational drugs, intraocular or periocular steroids, macular laser photocoagulation, photodynamic therapy, vitreoretinal surgery, intraocular surgery (study eye)~* Stroke or myocardial infarction during the 6-month period prior to baseline~* Systemic anti-VEGF therapy at any time.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6 mg (Type: EXPERIMENTAL): 3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62.
- Aflibercept 2 mg (Type: ACTIVE_COMPARATOR): 3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each participant who met the following criteria were enrolled in this study:~1. Who completed Visit 8 of study E2007-G000-304, E2007-G000-305, or E2007-G000-306 and complied with the inclusion and exclusion criteria for that study (excluding criteria that are related to seizure occurrences).~2. Provided written informed consent signed by participant or legal guardian prior to entering the study or undergoing any study procedures (If the written informed consent was provided by the legal guardian because the participant was unable to do so, a written or verbal assent from the participant was obtained).~3. Who was considered reliable and willing to be available for the study period and record seizures and report adverse events them self or have a caregiver who can record and report the events for them.~4. Females who were either of non-childbearing potential (defined as having undergone surgical sterilization, or postmenopausal \[\>age 50 and amenorrheic for 12 months\]) or of childbearing potential. Females of childbearing potential were enrolled only if they agreed to be abstinent or continue using at least 1 medically acceptable method of contraception (eg, a double-barrier method \[eg, condom + spermicide, condom + diaphragm with spermicide\], IUD, or have a vasectomised partner) throughout the study period and for 2 months after the last dose of study drug. Women using hormonal contraceptives were required to use an additional approved method of contraception (as described previously) continuously throughout the entire study period and for 2 months after the last dose of study drug. (It was not required for male subjects to use contraceptive measures based on preclinical toxicology data).~5. Continued to be treated with a stable dose of 1 or a maximum of 3 approved anti-epileptic drugs.~Exclusion Criteria:~Participants who met the following criteria were excluded from the study:~1. Those who, for any reason, discontinued early from the preceding double-blind study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a history of and current complaint of CLDE.~* Use properly fitted daily-wear soft contact lenses.~* Able to wear contact lenses for at least 8 hours a day.~* If female, are non-pregnant or non-lactating.~Exclusion Criteria:~* Have changed brand of contact lens or care solutions within one month prior to Visit 1.~* Use extended (overnight) wear contact lenses.~* Have a clinically significant ophthalmic abnormality.~* Have had cauterization of the punctum or have had punctal plugs (silicone or collagen) inserted or removed within the 90 days prior to the screening.~* Have any active ongoing ocular infection or ocular disease.~* Have a serious medical condition which could confound study assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- azithromycin ophthalmic solution, 1% (Type: EXPERIMENTAL): None
- rewetting drops (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2~Exclusion Criteria:~Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for PF-04991532 and sitagliptin
- 25 mg PF-04991532 (Type: EXPERIMENTAL): None
- 75 mg PF-04991532 (Type: EXPERIMENTAL): None
- 150 mg PF-04991532 (Type: EXPERIMENTAL): None
- 300 mg PF-04991532 (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* All patients with newly diagnosed NHL and HL~* Scheduled to receive anthracycline-based therapy~Exclusion Criteria:~* Statin use or Statin use is indicated based on guidelines~* Pregnancy or breastfeeding~* Unable to provide informed consent~* Unexplained persistent elevation of transaminases (\>3 times upper limits of normal)~* Concomitant use of cyclosporine~* Renal failure: estimated glomerular filtration \<45 mL/min/1.73 m2~* Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip~* LVEF of \<50% at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes for at least 180 days prior to screening and treated with stable basal insulin analogue dose of minimum 20 U/day with or without stable metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening (defined as insulin adjustments less than 10% during the past 8 weeks as assessed by the investigator)~* HbA1c (glycosylated haemoglobin A1c) 7.0-10.0% (both inclusive)~* Body mass index (BMI) 20-45 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Female of child-bearing potential who is pregnant, breast-feeding or intending to become pregnant~* Recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness~* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 12 weeks prior to screening~* Impaired liver or renal function~* Uncontrolled treated or untreated hypertension (systolic blood pressure (SBP) equal to or above 180 mmHg and/or diastolic blood pressure (DBP) equal to or above 100 mmHg)~* Any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial~* Known or suspected abuse of alcohol or narcotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0954A-264 Filter Study (0954A-264)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with mild to severe hypertension (SiDBP 90-120 mmHg)~Exclusion Criteria:~* Systolic BP \> 200 mmHg~* Secondary or malignant hypertension~* Taking more than 2 antihypertensive medications~* Hypertension induced by oral contraceptives~* Hx of cerebral vascular accident within 6 months~* Hx of angina, myocardial infarction, PCI, CABG, or decompensated CHF within 6 months~* Clinically significant AV conduction disturbance or potentially life threatening ventricular arrhythmias, valvular disease, cardiomyopathy, unexplained syncope~* History of angioedema~* Sensitivity to AII receptor antagonists or HCTZ, nephrotic syndrome,single kidney function~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a body mass index (BMI) of 18.0-30.0 kg/m\^2, inclusive, at Visit 1 and Visit 2~* Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia~* Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1~* Subject has maintained a stable body weight (change \</= 5%) for at least 3 months prior to Visit 1 based on self-report~* Additional criteria may apply~Exclusion Criteria:~* Subject has any of the following psychiatric conditions per DSM-5 criteria:~* Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder~* Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study~* Drug-induced or toxic psychosis~* Any other psychiatric condition that could interfere with participation in the study~* Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator~* Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Administered as a coated bilayer tablet
- Olanzapine (Type: ACTIVE_COMPARATOR): Administered as a coated bilayer tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Peri or Post menopausal women either:~  * without symptoms but with risk factors for heart disease OR~ * experiencing atypical chest pain, OR~ * experiencing exertional dyspnea AND 2 or more risk factors for CAD~* Must be able to perform an exercise stress test~Peri-or post-menopausal (including surgical menopause) based on history.~* Post-menopausal is defined as females age 40-65 who self-report the absence of menstrual periods for at least 12 months.~* Peri-menopausal is defined as females age 40-65 who self-report the absence or irregularity of menstrual periods for 6-12 months.~* Surgical menopause is defined as females who have had a bilateral salpingo-oophorectomy with or without hysterectomy.~Exclusion Criteria:~* Previous confirmed heart disease

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Definity (Type: EXPERIMENTAL): All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PSC established by alkaline phosphatase \>1.5 times and/or two fold elevation of liver transaminases (AST and/or ALT) for at least 6 months duration.~* Cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction, beading, or narrowing consistent with PSC.~* Both genders.~* Age ≥ 18 years old and \< than 75 years old.~* Patient's informed consent for study participation.~Exclusion Criteria:~* Treatment with systematic antibiotics, azulfidine, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, tacrolimus, silymarin or prednisone in the preceding three months.~* Active drug or alcohol use.~* Prior history of allergic reactions to the antibiotics which will be used in the study.~* Any condition that, in the opinion of the investigator, would interfere with the patients' ability to complete the study safely or successfully.~* Evidence of decompensated liver disease such as recurrent variceal bleeding, refractory ascites or spontaneous hepatic encephalopathy.~* Anticipated need for transplantation in one year (Mayo survival model \<80% one-year survival without transplant).~* Findings highly suggestive of liver disease of other etiology such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis or secondary sclerosing cholangitis.~* Pregnancy or current lactation. Subjects becoming pregnant during the study will be withdrawn.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vancomycin 125 mg orally 4 times a day (Type: EXPERIMENTAL): The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
- Vancomycin 250 mg orally 4 times a day (Type: EXPERIMENTAL): None
- Metronidazole 250 mg orally 3 times a day (Type: EXPERIMENTAL): None
- Metronidazole 500 mg orally 3 times a day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete